What is the procedure and diagnostic criteria for the oral glucose tolerance test in adults and pregnant women?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Oral Glucose Tolerance Test: Procedure and Diagnostic Criteria

Non-Pregnant Adults

For non-pregnant adults, use the fasting plasma glucose test as the preferred diagnostic method, reserving the 75-gram OGTT for patients with fasting glucose <126 mg/dL who have symptoms suggestive of diabetes complications. 1

Test Preparation

  • Patients must consume at least 150 grams of carbohydrate daily for 3 consecutive days before testing 2
  • Maintain unlimited physical activity in the days preceding the test 2
  • Fast for 8-14 hours overnight before the test 2
  • The test must be performed in the morning 2
  • Patients should remain seated throughout the test and not smoke 2

Test Administration

  • Administer 75 grams of anhydrous glucose dissolved in water 2
  • Measure venous plasma glucose at fasting, 1-hour, and 2-hour time points 2

Diagnostic Thresholds (Non-Pregnant)

  • Fasting plasma glucose ≥126 mg/dL 2
  • 2-hour plasma glucose ≥200 mg/dL 2
  • Confirm diagnosis by repeat testing on a different day unless unequivocal hyperglycemia is present 2

Important Caveat

The OGTT is poorly reproducible and difficult to perform in routine practice, making fasting plasma glucose the preferred test for most non-pregnant adults 1. The OGTT should never be used to evaluate reactive hypoglycemia 3.


Pregnant Women

All pregnant women without pre-existing diabetes must be screened for gestational diabetes mellitus (GDM) at 24-28 weeks gestation using either a one-step 75-gram OGTT or a two-step approach. 4

Timing of Screening

Standard Risk Women

  • Screen at 24-28 weeks gestation 4
  • This window corresponds to peak pregnancy-related insulin resistance 4
  • Do not postpone screening beyond 28 weeks—this timing is critical for timely intervention to reduce adverse maternal-fetal outcomes 4

High-Risk Women (Early Screening)

Perform glucose testing at the first prenatal visit (12-14 weeks) if any of the following are present: 4

  • BMI ≥30 kg/m² 4
  • Prior history of GDM 4
  • Glycosuria 4
  • First-degree relative with diabetes 4

If early testing is negative, retest at 24-28 weeks 4

Low-Risk Women (May Omit Screening)

Women meeting all of the following criteria may forgo GDM screening: 4

  • Age <25 years
  • Pre-pregnancy BMI ≤25 kg/m²
  • No first-degree relative with diabetes
  • No prior abnormal glucose tolerance
  • No history of adverse obstetric outcomes
  • Ethnic group with low diabetes prevalence

Two Screening Approaches for Pregnancy

One-Step Approach (IADPSG/ADA Recommended)

The one-step 75-gram OGTT is the preferred method, identifying approximately 15-20% of pregnancies with GDM. 4

Test Preparation

  • 8-14 hour overnight fast 4
  • ≥150 grams carbohydrate daily for 3 days before testing 4
  • Patient must remain seated and not smoke during the test 4

Test Administration

  • Administer 75 grams glucose after overnight fast 4
  • Measure plasma glucose at fasting, 1-hour, and 2-hour 4

Diagnostic Thresholds (One-Step)

GDM is diagnosed when ANY ONE value meets or exceeds: 1, 4

  • Fasting ≥92 mg/dL (5.1 mmol/L) 1
  • 1-hour ≥180 mg/dL (10.0 mmol/L) 1
  • 2-hour ≥153 mg/dL (8.5 mmol/L) 1

These thresholds are based on the HAPO study, which demonstrated continuous, graded increases in adverse outcomes (macrosomia, cesarean delivery, neonatal hypoglycemia, shoulder dystocia) as maternal glucose rises, without a clear safety threshold 1.


Two-Step Approach (ACOG-Supported)

The two-step approach identifies approximately 5-6% of pregnancies with GDM, missing milder cases but requiring fewer women to undergo full diagnostic testing. 4

Step 1: Initial Screening

  • Administer 50-gram glucose challenge (non-fasting) at 24-28 weeks 4
  • Measure plasma glucose at 1 hour 4
  • If 1-hour glucose is ≥130,135, or 140 mg/dL (threshold varies by institution), proceed to Step 2 4

Step 2: Diagnostic Test

  • Perform 100-gram OGTT after overnight fast 4
  • Measure plasma glucose at fasting, 1-hour, 2-hour, and 3-hour 4

Diagnostic Thresholds (Two-Step, Carpenter-Coustan Criteria)

GDM is diagnosed when AT LEAST TWO values meet or exceed: 4, 5

  • Fasting ≥95 mg/dL (5.3 mmol/L) 5
  • 1-hour ≥180 mg/dL (10.0 mmol/L) 5
  • 2-hour ≥155 mg/dL (8.6 mmol/L) 5
  • 3-hour ≥140 mg/dL (7.8 mmol/L) 5

Important note: ACOG acknowledges that in clinical practice, a single elevated value may be used for diagnosis, though traditional criteria require two abnormal values 4, 5.


Critical Pitfalls to Avoid

Do Not Use Fasting Glucose Alone at 24-28 Weeks

Using only fasting plasma glucose at 24-28 weeks is NOT validated and results in massive under-diagnosis of GDM. 4 The 1-hour and 2-hour post-load values independently predict macrosomia and adverse outcomes 4. A complete OGTT with all three time points is mandatory 4.

Early Pregnancy Exception

Fasting glucose alone may be used only at the first prenatal visit (early pregnancy) in high-risk women: 4

  • Fasting glucose ≥92 mg/dL but <126 mg/dL diagnoses GDM
  • Fasting glucose ≥126 mg/dL indicates overt diabetes (not GDM)

These early-pregnancy thresholds do not apply to standard 24-28 week screening 4.

Do Not Use Urine Glucose Testing

Urine glucose testing is not useful for GDM screening or management and should be avoided 4.

Do Not Apply IADPSG Thresholds Before 24 Weeks

The IADPSG diagnostic thresholds were derived from data collected at 24-32 weeks and should not be applied earlier in pregnancy 4.


Choosing Between One-Step and Two-Step

In high-risk populations, the one-step strategy is more cost-effective and identifies a larger number of women with milder hyperglycemia who still benefit from treatment. 4 The two-step approach reduces the number of women requiring full diagnostic testing but may miss milder cases of GDM 4. Both strategies are acceptable; the choice depends on practice setting, GDM prevalence in the population, and available resources 4.


Postpartum Follow-Up

All women diagnosed with GDM must undergo a 75-gram OGTT at 4-12 weeks postpartum using non-pregnancy diagnostic criteria to detect persistent diabetes or prediabetes 5. Women with prior GDM have a 3.4-fold increased risk of developing type 2 diabetes and require lifelong diabetes screening every 2-3 years 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Oral Glucose Tolerance Test Procedure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guidelines for Oral Glucose Tolerance Testing in Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Diagnostic Criteria and Management of Gestational Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What are the American College of Obstetricians and Gynecologists (ACOG) guidelines for the 1-hour glucose challenge test (GCT) in early pregnancy?
What is the management plan for a pregnant individual with glucosuria (glucose in the urine)?
Can an Oral Glucose Tolerance Test (OGTT) be performed at 19 weeks gestation in a pregnant woman?
Should an Oral Glucose Challenge Test (OGCT) be performed in a patient with colestasis of pregnancy?
What are the guidelines for gestational diabetes screening and management?
Which respiratory sign indicates immediate endotracheal intubation in a patient with suspected anaphylaxis?
Does platelet transfusion worsen thrombosis in acute pulmonary embolism?
What is the appropriate diagnosis and treatment for a fracture of the surgical neck of the humerus?
For a type 2 diabetic patient with HbA1c 6.7%, fasting glucose 7.2 mmol/L, total cholesterol 8.5 mmol/L, LDL‑C 6.9 mmol/L, uric acid 468 µmol/L, currently on gliclazide 60 mg twice daily, sitagliptin 100 mg once daily, atorvastatin 40 mg once daily, and febuxostat 40 mg once daily, can I continue this regimen and what additional medication should be added?
What are the indications for folic acid supplementation?
In an adult with normal renal function being stepped down from IV ceftriaxone for Escherichia coli pyelonephritis, should the oral beta‑lactam (β‑lactam) dose be higher than standard, such as amoxicillin‑clavulanate (Augmentin) 1 g three times daily or cefpodoxime 400 mg twice daily?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.